Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 2, pp. 311-322
Closed Access | Times Cited: 23

Showing 23 citing articles:

Applications of protein ubiquitylation and deubiquitylation in drug discovery
Yilin Chen, Haoan Xue, Jianping Jin
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107264-107264
Open Access | Times Cited: 16
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp
Bioorganic & Medicinal Chemistry (2024) Vol. 105, pp. 117718-117718
Open Access | Times Cited: 8
Modulating the phosphorylation status of target proteins through bifunctional molecules
Qindi He, Zhijie Wang, Rongrong Wang, et al.
Drug Discovery Today (2025), pp. 104307-104307
Closed Access | Times Cited: 1
Mechanism of degrader-targeted protein ubiquitinability
Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 7
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Chrysanthi Kagiou, José A. Cisneros, Jakob Farnung, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Mechanism of degrader-targeted protein ubiquitinability
Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, et al.
Science Advances (2024) Vol. 10, Iss. 41
Open Access | Times Cited: 5
Clozapine as an E3 Ligand for PROTAC Technology
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 258-262
Closed Access
Selective degradation of BRD9 by a DCAF16-recruiting targeted glue: mode of action elucidation and in vivo proof of concept
Scott J. Hughes, Wojciech J. Stec, Colin Davies, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Implications of frequent hitter E3 ligases in targeted protein degradation screens
Xiaoyu Zhang, Gabriel M. Simon, Benjamin F. Cravatt
Nature Chemical Biology (2025)
Closed Access
Characteristics of the Kelch domain containing (KLHDC) subfamily and relationships with diseases
Courtney Pilcher, Paula Armina V. Buco, Jia Q. Truong, et al.
FEBS Letters (2025)
Open Access
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
Shiqing Li, Tao Zeng, Zhixing Wu, et al.
Journal of the American Chemical Society (2025)
Closed Access
Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains
Chuhui Huang, Claire L. Harris, Ghizal Siddiqui, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 4, pp. 978-1012
Closed Access
Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
(2024)
Open Access | Times Cited: 3
New therapies on the horizon: Targeted protein degradation in neuroscience
James A Gregory, Christopher M. Hickey, Juan D. Chavez, et al.
Cell chemical biology (2024) Vol. 31, Iss. 9, pp. 1688-1698
Open Access | Times Cited: 3
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
Yerim Jin, Yeongju Lee
ChemMedChem (2024) Vol. 19, Iss. 23
Open Access | Times Cited: 2
Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2
Daniel C. Scott, Suresh Dharuman, Elizabeth C. Griffith, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Drug Discovery Approaches to Target E3 Ligases
A. Rodríguez-Gimeno, Carles Galdeano
ChemBioChem (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 2
A C-Degron Structure-Based Approach for the Development of Ligands Targeting the E3 Ligase TRIM7
Christian J. Muñoz Sosa, Christopher Lenz, Anton Hamann, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 7, pp. 1638-1647
Closed Access | Times Cited: 1
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Fragment-based approaches to discover ligands for tumor-specific E3 ligases
Junhyeong Yim, S S Kim, Hyung Ho Lee, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-14
Closed Access
Structural basis for C-degron selectivity across KLHDCX family E3 ubiquitin ligases
Daniel C. Scott, Sagar Chittori, Nicholas Purser, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Page 1

Scroll to top